Erenumab

AIMOVIG

What it isCGRP receptor antibody; migraine prevention.

Why this oneIt is the only marketed CGRP monoclonal antibody that blocks the receptor rather than the ligand.

What limits itConstipation can be severe, and blood pressure can rise. Cost and prior authorization are practical barriers.

FDA-approved for

FDA dosing	Population	Start	Target	Max
Preventive treatment of migraine	adult	70 mg SC once monthly	70 mg SC once monthly; some patients 140 mg once monthly	140 mg once monthly

Renal Undefined

Hepatic Undefined

Subcutaneous use only (abdomen, thigh, or upper arm)
Before use, let sit at room temperature >=30 min protected from sunlight; do not warm or shake
Patient self-administration via single-dose prefilled autoinjector or syringe
If a dose is missed, give as soon as possible, then schedule monthly from the last dose

Hypersensitivity reactions (rash, angioedema, anaphylaxis) — may occur hours to >1 week after dosing
Constipation with serious complications (some requiring hospitalization/surgery)
New-onset or worsening hypertension
New-onset or worsening Raynaud's phenomenon

Pregnancy No adequate human data; animal studies showed no adverse effects on offspring.

Lactation No data on presence in human milk; weigh benefits against clinical need.

NO BOXED WARNINGS

Principal riskConstipation, which can be severe; hypertension

Cost, est. cash$500–$1,200/month

Generic entry2034 est. (biosimilar)

Therapeutic safety burden1 / 4

Overdose danger1 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityConstipation and hypertension are the principal serious concerns; acute overdose toxicity is low.

no kinetic interactions